BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Olverembatinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Olverembatinib\, from ClinicalTrials.gov 
 estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06757855-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Olverembatinib: Phase 1/2 readout est. (NCT06757855)
DESCRIPTION:Olverembatinib\, phase 1/2.\nStudy: Olverembatinib Combined Wit
 h Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML\nEs
 timated primary completion: 1 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/olverembatinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06757855
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05495035-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olverembatinib: Phase 1 readout est. (NCT05495035)
DESCRIPTION:Olverembatinib\, phase 1.\nStudy: Study for Safety and Efficacy
  of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refrac
 tory Ph + ALL\nEstimated primary completion: 31 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/olverembatinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05495035
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06401603-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Olverembatinib: Phase 1 readout est. (NCT06401603)
DESCRIPTION:Olverembatinib\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Ph
 ase I Study of Decitabine\, Lisaftoclax\, and Olverembatinib in Patients W
 ith Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive
  Acute Myeloid Leukemia\nEstimated primary completion: 1 January 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/olverembatinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06401603
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06817720-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270307
DTEND;VALUE=DATE:20270308
SUMMARY:Olverembatinib: Phase 2 readout est. (NCT06817720)
DESCRIPTION:Olverembatinib\, phase 2\, Chronic Myeloid Leukemia.\nStudy: Ph
 ase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monothe
 rapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Fail
 ing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor o
 r Asciminib\nEstimated primary completion: 7 March 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/olverembatinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06817720
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06640361-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Olverembatinib: Phase 3 readout est. (NCT06640361)
DESCRIPTION:Olverembatinib\, phase 3.\nStudy: A Study of Olverembatinib in 
 SDH-deficient GIST.\nEstimated primary completion: 31 March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/olverembatinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06640361
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06423911-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Olverembatinib: Phase 3 readout est. (NCT06423911)
DESCRIPTION:Olverembatinib\, phase 3\, Chronic Myeloid Leukemia.\nStudy: St
 udy of Olverembatinib (HQP1351) in Patients With CML-CP\nEstimated primary
  completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/olverembatinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06423911
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06658925-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Olverembatinib: Phase 2 readout est. (NCT06658925)
DESCRIPTION:Olverembatinib\, phase 2.\nStudy: Olverembatinib as Maintenance
  Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL\nEstimated primar
 y completion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/olverembatinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06658925
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07443488-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Olverembatinib: Phase 2 readout est. (NCT07443488)
DESCRIPTION:Olverembatinib\, phase 2.\nStudy: Efficacy and Safety of Olvere
 mbatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Fo
 llowed by HSCT in Ph+ ALL\nEstimated primary completion: 31 October 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/olverembatinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07443488
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03594422-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olverembatinib: Phase 1 readout est. (NCT03594422)
DESCRIPTION:Olverembatinib\, phase 1.\nStudy: A Study of HQP1351 in Patient
 s With GIST or Other Solid Tumors\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/olverembatinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0359
 4422
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06051409-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olverembatinib: Phase 3 readout est. (NCT06051409)
DESCRIPTION:Olverembatinib\, phase 3.\nStudy: A Study of Olverembatinib in 
 Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/olverembatinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06051409
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07454226-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Olverembatinib: Phase na readout est. (NCT07454226)
DESCRIPTION:Olverembatinib\, phase na.\nStudy: ABL/JAK Inhibitors With Chem
 otherapy and Venetoclax for Ph-like ALL\nEstimated primary completion: 1 M
 arch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olverembat
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07454226
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493161-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olverembatinib: Phase na readout est. (NCT07493161)
DESCRIPTION:Olverembatinib\, phase na.\nStudy: Chemotherapy With Targeted-I
 mmunotherapy for Newly Diagnosed Ph+ ALL\nEstimated primary completion: 31
  March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olveremb
 atinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07493161
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840976-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Olverembatinib: Phase 2 readout est. (NCT07840976)
DESCRIPTION:Olverembatinib\, phase 2.\nStudy: Immunotargeted Therapy Plus L
 ow-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL\nEstimated primary
  completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/olverembatinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07840976
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04501120-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Olverembatinib: Phase 1/2 readout est. (NCT04501120)
DESCRIPTION:Olverembatinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: St
 udy of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in
  Patients Relapsed/Refractory AML\nEstimated primary completion: September
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/olverembatinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT045
 01120
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152041-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Olverembatinib: Phase 3 readout est. (NCT07152041)
DESCRIPTION:Olverembatinib\, phase 3.\nStudy: Newly-diagnosed Pediatric Ph-
 positive B-ALL Protocol\nEstimated primary completion: December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/olverembatinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07152041
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04260022-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20291227
DTEND;VALUE=DATE:20291228
SUMMARY:Olverembatinib: Phase 1 readout est. (NCT04260022)
DESCRIPTION:Olverembatinib\, phase 1\, Chronic Myeloid Leukemia.\nStudy: St
 udy of HQP1351 in Subjects With Refractory CML and Ph+ ALL\nEstimated prim
 ary completion: 27 December 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/olverembatinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04260022
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178912-2925@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Olverembatinib: Phase 2 readout est. (NCT07178912)
DESCRIPTION:Olverembatinib\, phase 2.\nStudy: Phase II Study of the Combina
 tion of Subcutaneous Blinatumomab and Olverembatinib in Patients With Phil
 adelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphobl
 astic Leukemia (ALL)\nEstimated primary completion: 30 September 2031. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/olverembatinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07178912
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
